Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-08-29
2010-10-05
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S388230
Reexamination Certificate
active
07807160
ABSTRACT:
Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
REFERENCES:
patent: 6096289 (2000-08-01), Goldenberg
patent: 6495667 (2002-12-01), Bazan
patent: 2007/0009526 (2007-01-01), Benson et al.
patent: WO 00/53631 (2000-09-01), None
patent: WO 01/18051 (2001-03-01), None
patent: WO 2004/071517 (2004-08-01), None
patent: WO 2004/081190 (2004-09-01), None
patent: WO 2005/047324 (2005-05-01), None
patent: WO 2005/047326 (2005-05-01), None
patent: WO 2005/052157 (2005-06-01), None
patent: WO 2007/005955 (2007-01-01), None
patent: WO 2007/024846 (2007-03-01), None
MacCallum et al. (J. Mol. Biol. (1996) 262:732-745).
De Pascalis et al. The Journal of Immunology (2002) 169, 3076-3084.
Casset et al. (2003) BBRC 307, 198-205.
Vajdos et al. (2002) J. Mol. Biol. 320, 415-428.
Holm et al (2007) Mol. Immunol. 44: 1075-1084.
Chen et al. J. Mol. Bio. (1999) 293, 865-881.
Wu et al. J. Mol. Biol. (1999) 294, 151-162.
Brummell et al. (Biochemistry 32:1180-1187 (1993)).
Kobayashi et al. (Protein Engineering 12:879-844 (1999)).
Burks et al. (PNAS 94:412-417 (1997)).
Jang et al. (Molec. Immunol. 35:1207-1217 (1998)).
Brorson et al. (J. Immunol. 163:6694-6701 (1999)).
Coleman (Research in Immunol. 145:33-36 (1994)).
Salfeld (Nature Biotech. 25(12): 1369-1372 (2007)).
Dall'Acqua (J. Immunol. 177:1129-1138 (2006)).
Voskoglou-Nomikos (Clin. Can. Res. 9:4227-4239 (2003)).
Dennis (Nature 442:739-741 (2006)).
Bowman et al. (Curr. Opin. Infect. Dis. 19:245-252 (2006)).
Chen, et al. (2006)J. Clinical Investigation116(5):1317-1326 “Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis”.
Sehy, et al. (2005) FASEBJournalvol. 19, No. 4, Suppl. S, Part 1, pp. A945-A946 “Unambiguous detection of IL-23 (p19/p40) protein in native samples using a novel enzyme-linked immunosorbent assay”.
Barbie & Lefranc (1998)Experimental and Clinical Immunogenetics, 15:171-183 “The Human Immunoglobulin Kappa Variable (IGKV) Genes and Joining (IGKJ) Segments”.
Chothia & Lesk (1987)J. Mol. Biol. 196: 901-917 “Canonical Structures for the Hypervariable Regions of Immunoglobulins”.
Cua & Kastelein (2006)Nat. Immunol. 7:557-559 “TGF-B, a ‘double agent’ in the immune pathology war”.
Dong (2006)Nat. Rev. Immunol. 6(4):329-333 “Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells”.
Gorman et al. (1991)Proc. Natl. Acad. Sci. USA88:4181 “Reshaping a therapeutic CD4 antibody”.
Hodgson (1991)Biotechnology(NY) 9:421-5 “Making Monoclonals in Microbes”.
Iwakura & Ishigame (2006)J. Clin. Invest. 116:1218-1222 “The IL-23/IL-17 axis in inflammation”.
Jones et al. (1986)Nature321:522-525 “Replacing the complementarity-determining regions in a human antibody with those from a mouse”.
Kabat & Wu (1991)J. Immunol. 147:1709 “Identical V Region Amino Acid Sequences and Segments of Sequences in Antibodies of Different Specificities”.
Lefranc (2001)Experimental and Clinical Immunogenetics18:100-116 “Nomenclature of the Human Immunoglobulin Heavy (IGH) Genes”.
Lefranc (2001)Experimental and Clinical Immunogenetics18:161-174 “Nomenclature of the Human Immunoglobulin Kappa (IGK) Genes”.
Oppmann, et al. (2000)Immunity13:715-725 “Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12”.
Parham, et al.(2002)J Immunol168:5699-708 “A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12RB1 and a Novel Cytokine Receptor Subunit, IL-23R”.
Presta (2005)J. Allergy Clin. Immunol. 116:731-736 “Selection, design, and engineering of therapeutic antibodies”.
Queen et al. (1989)Proc. Natl. Acad. Sci. USA86:10029 “A humanized antibody that binds to the interleukin 2 receptor”.
Reichmann et al. (1988)Nature332:323-329 “Reshaping human antibodies for therapy”.
Tato & O'Shea (2006)Nature441:166-168 “What does it mean to be just 17?”.
Veldhoen (2006)Immunity24:179-189 TGFB in the Context of an Inflammatory Cytokine Milieu Supports De Novo Differentiation of IL-17-Producing T Cells.
Verhoeyen et al. (1988)Science239:1534-1536 “Reshaping Human Antibodies: Grafting an Antilysozyme Activity”.
Wiekowski, et al. (2001)J. Immunol. 166:7563-7570 “Ubiquitous Transgenic Expression of the IL-23 Subunit p19 Induces Multiorgan Inflammation, Runting, Infertility, and Premature Death”.
Rudikoff, et al. (1982)Proc. Natl. Acad. Sci. USA79:1979-1983 “Single amino acid substitution altering antigen-binding specificity”.
R&D Systems,de novo: New Products from R&D Systems, Mar. 2004, pp. 1-10.
R&D Systems,de novo: New Products from R&D Systems, Jun. 2005, pp. 1-12.
Verreck et al. (2004)PNAS101(13):4560-4565, “Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria”.
Beyer Brian M.
Ingram Richard N.
Liu Yan-Hui
Orth Peter
Presta Leonard G.
Bellomy Gregory R.
Bristol Lynn
Mohan-Peterson Sheela
Schering Corporation
LandOfFree
Engineered anti-IL-23 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Engineered anti-IL-23 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Engineered anti-IL-23 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4214431